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Abstract
Background: The impact of cumulative dose of cisplatin on clinical outcomes of nasopharyngeal carcinoma (NPC)
patients who received intensity-modulated radiotherapy (IMRT) was evaluated.
Methods: This study included 491 consecutive patients with histologically confirmed NPC who were treated
with concurrent chemoradiotherapy with IMRT. The patients were divided into three groups: low- (cumulative
dose ≤100 mg/m2), medium- (cumulative dose >100 mg/m2 and ≤200 mg/m2), and high- (cumulative dose >200 mg/m2)
dose groups. Subgroups of patients included pre-treatment levels of Epstein–Barr Virus DNA (EBV DNA) <4000 copies/ml
and pre-treatment EBV DNA ≥4000 copies/ml. To test for independent significance, the Kaplan–Meier with the log–rank
test and the Cox proportional hazards model were used.
Results: The 5-year overall survival (OS) rates of the low-, medium-, and high-dose groups were 64.1 %, 91.1 %, and
89.4 %, respectively (P = 0.002). Based on multivariate analysis, patients who were in the medium- and high-dose
groups had compared with the low-dose group, with an odds ratio of 0.135 (95 % CI 0.045–0.405, P < 0.001) and 0.225
(95 % CI 0.069–0.734, P = 0.013), respectively. For the low-risk patients, the cumulative dose of cisplatin significantly
associated with a lower OS (P < 0.001). The medium-dose group had reduced odds of death compared with the low-
dose group, with an odds ratio of 0.062 (95 % CI 0.001–0.347, P = 0.002), according to multivariate analysis.
Conclusions: The cumulative dose of cisplatin is associated with OS and distant metastasis-free survival (DMFS) among
NPC patients who received IMRT.
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Background
Nasopharyngeal carcinoma (NPC) is endemic in Asia,
particularly the classical nonkeratinizing type. NPC
differs from other head and neck cancers by its distinctly
skewed geographic and ethnic distribution, its associ-
ation with Epstein–Barr virus (EBV), its aggressive
natural behaviour with an especially high predilection
propensity for distant metastases, and special therapeutic
considerations [1]. Currently, concurrent cisplatin-based
chemotherapy administered during the course of radio-
therapy is considered to be the standard of care for
advanced NPC. Cisplatin-based regimens delivered ei-
ther once per week (30–40 mg/m2) or once every three
weeks (100 mg/m2) are accepted as standard practice for
concurrent chemotherapy [2–4]. Meta-analyses of ran-
domised controlled trials and phase III studies have
concluded that the addition of any type of chemotherapy
to definitive RT can improve clinical outcomes [3–11].
The dose intensity of chemotherapy administered during
radiotherapy has been shown to have prognostic signifi-
cance in NPC treatment, but these associations were
mostly based on conventional two-dimensional (2D) and
three-dimensional conformal techniques [12–14]. With
the development of radiation techniques, there is now
little controversy that intensity-modulated radiotherapy
(IMRT) is preferred for the treatment of NPC, if re-
sources permit; dosimetric studies have shown that this
procedure could improve dose conformity for complex
tumour targets and improve the protection of adjacent
organs. Together with chemotherapy, all IMRT series
have reported excellent results, with local controls
exceeding 90 % and 3-year disease-free survival rates of
over 80 % [15–18]. Therefore, it is of great importance
to identify the optimal cumulative dose of cisplatin for
concurrent chemoradiotherapy (CCRT) in patients with
NPC who receive IMRT.
In this study, we aimed to compare the long-term
survival outcomes of the different cumulative doses of
cisplatin that were delivered concurrently with IMRT in
patients with NPC. Our findings will help guide clinical
CCRT treatment strategies in NPC.
Methods
Ethics statement
This retrospective study was approved by the Clinical
Research Ethics Committee of the Sun Yat-sen University
Cancer Center, and all the participants provided written
informed consent before treatment. This study is in
compliance with the Helsinki Declaration. Patient records
were anonymized and de-identified prior to analysis.
Patients
This study retrospectively analysed data from 491 con-
secutive patients with histologically confirmed NPC who
were treated with concurrent chemoradiotherapy between
December 2006 and December 2010 at Sun Yat-sen
University Cancer Center. Inclusion criteria for the
patients consisted of (1) histologically confirmed NPC by
biopsy of the nasopharynx, (2) no distant metastasis, (3)
no treatment prior to admission, (4) no other tumour
types or serious illnesses, (5) an Eastern Cooperative
Oncology Group (ECOG) performance score ≤2, (6)
received radical IMRT during the course of treatment,
and (7) received concurrent chemotherapy with cisplatin.
In all patients, the staging workup included an MRI of the
head and neck, a chest radiograph, a bone scintigraphy,
and an ultrasonography of the abdominal region. Patients
who received neoadjuvant chemotherapy were ineligible.
All participants were restaged according to the Seventh
Edition of the American Joint Committee on Cancer
(AJCC) staging system. There were 42, 328, and 121
patients with stage II, III, and IVa-b disease, respect-
ively. Patients were divided into three groups, i.e., low-
dose (cumulative dose ≤100 mg/m2), medium-dose
(100 mg/m2 < cumulative dose ≤ 200 mg/m2), and high-
dose (cumulative dose >200 mg/m2), according to
previous studies [12, 14]. Table 1 shows the clinicopatho-
logical features in the study population of 491 patients.
Treatment
The target volumes were delineated using a previously
described institutional treatment protocol [19], in ac-
cordance with the International Commission on Radi-
ation Units and Measurements reports 50 and 62. All
target volumes were delineated slice-by-slice on the
treatment planning computed tomography scan. The
primary nasopharyngeal gross tumour volume (GTVnx)
and the involved cervical lymph nodes were determined
based on the imaging, clinical, and endoscopic findings.
The enlarged retropharyngeal nodes were outlined, to-
gether with primary gross tumour volume (GTV), as the
GTVnx on the IMRT plans. The first clinical tumour
volume (CTV1) was defined as the area from 0.5 to
1.0 cm outside the GTV, a site that involves potential
sites of local infiltration. Clinical target volume 2
(CTV2) was defined as the margin from 0.5 to 1.0 cm
around CTV1 and the lymph node draining area (Levels
II, III, and IV). For stage N1–3 patients, the lower neck
area received conventional anterior cervical field radi-
ation with a midline shield to 50 Gy in daily fractions of
2 Gy. For patients with stage N0 disease, RT was not
delivered to the lower neck area. The prescribed dose
was 66–70 Gy to the planning target volume (PTV) of
GTVnx (PTVnx), 60 Gy to PTV1, 54 Gy to PTV2, and
60–66 Gy to PTV of the involved cervical lymph nodes
in 30 to 33 fractions. In total, 30–33 fractions were
administered at 1 fraction per day, 5 days/week. The
IMRT plan was designed in accordance with previous
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Table 1 Baseline characteristics of 491 patients with nasopharyngeal carcinoma
Low-dose group 14(2.9 %) Medium-dose group 378(77.0 %) High-dose group 99(20.2 %) P value
Age(yr.), 0.081
<45 7(50.0 %) 170(45.0 %) 57(57.6 %)
≥45 7(50.0 %) 208(55.0 %) 42(42.4 %)
Gender 0.284
Female 6(42.9 %) 103(27.2 %) 132(26.9 %)
Male 8(57.1 %) 275(72.8 %) 359(73.1 %)
T stage 0.960
1 1(7.1 %) 23(6.1 %) 7(7.1 %)
2 2(14.3 %) 68(18.0 %) 15(15.2 %)
3 7(50.0 %) 217(57.4 %) 57(57.6 %)
4 4(28.6 %) 70(18.5 %) 20(20.3 %)
N stage 0.306
0 2(14.3 %) 55(14.6 %) 8(8.1 %)
1 8(57.1 %) 140(37.0 %) 47(47.5 %)
2 4(28.6 %) 159(42.1 %) 38(38.4 %)
3 0(0) 24(6.3 %) 6(6.1 %)
Clinical stage 0.492
2 3(21.4 %) 30(7.9 %) 9(9.1 %)
3 8(57.1 %) 256(67.7 %) 64(64.6 %)
4 3(21.4 %) 92(24.3 %) 26(26.3 %)
WHO type 0.418
2 0(0) 15(4.5 %) 7(7.6 %)
3 12(100.0 %) 316(95.5 %) 85(92.4 %)
ECOG score 0.859
0 0(0) 8(2.1 %) 2(2.0 %)
1 14(100.0 %) 370(97.9 %) 97(98.0 %)
ACE-27 0.159
0 8(57.1 %) 296(78.1 %) 78(78.8 %)
1 5(35.7 %) 71(18.7 %) 21(21.2 %)
2 1(7.1 %) 12(3.2 %) 0(0)
3 0(0) 0(0) 0(0)
EBV DNA 0.942
≥4000 8(57.1 %) 232(61.4 %) 60(60.6 %)
<4000 6(42.9 %) 146(38.6 %) 39(39.4 %)
RT Dose(Gy), Median(range) 68.0(68.0-70.0) 68.0(66.0-70.0) 68.0(66.0-70.0) 0.359
VCA-IgA 0.431
Positive(≥1:80) 10(71.4 %) 314(83.1 %) 79(79.8 %)
Negative(<1:80) 4(28.6 %) 64(16.9 %) 20(20.2 %)
EA-IgA 0.425
Positive(≥1:10) 8(57.1 %) 276(73.0 %) 72(72.7 %)
Negative(<1:10) 6(42.9 %) 102(27.0 %) 27(27.3 %)
Median follow-up in months(range) 46.5(3–80) 48(1–88) 53(11–86) 0.018
Abbreviations: yr year, WHO World Health Organization, ECOG Eastern Cooperative Oncology Group, EBV DNA Epstein–Barr virus deoxyribonucleic acid,
RT radiotherapy
P value < 0.05 indicates a statistically significant difference
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studies conducted at the Sun Yat-sen University Cancer
Center [20, 21].
Concurrent cisplatin chemotherapy was delivered to
all of the patients. Chemotherapy was initiated on the
same day as IMRT, and the cisplatin regimen included
intravenous infusion (IV) of 80–100 mg/m2 cisplatin
every 3 weeks or of 30–40 mg/m2 IV cisplatin weekly.
Among all of the 491 patients, 14 (2.9 %) had a cumula-
tive dose of cisplatin less than or equal to 100 mg/m2,
378 (77.0 %) had a cumulative dose of cisplatin >100
and ≤200 mg/m2, and 99 (20.2 %) had a cumulative dose
of cisplatin more than 200 mg/m2 during treatment.
Follow-up
The follow-up duration was calculated from the first day
of treatment to either the day of death or the day of the
last examination. Patients were examined at least every
3 months during the first 2 years; thereafter, follow-up
examinations were performed every 6 months for 3 years
or until death. The median follow-up period for the en-
tire patient cohort was 49 months (range 1–88 months).
Statistical analysis
The program Statistical Package for Social Sciences ver-
sion 17 (SPSS Inc., Chicago, IL, USA) was used for ana-
lysis. The Kruskal–Wallis test and Fisher’s exact test
were used to analyse the relationship among the low-
(cumulative dose ≤100 mg/m2), medium- (100 mg/m2 <
cumulative dose ≤ 200 mg/m2), and high- (cumulative
dose > 200 mg/m2) dose groups among all of the NPC
patients. Survival curves were estimated using the prod-
uct limit method of Kaplan–Meier with the log-rank
test. Univariate analysis was conducted using the log-rank
test, and multivariate analyses were calculated using the
Cox proportional hazards regression model. The poten-
tially important prognostic factors considered in the
modelling process included the following: patient gender
(1. female, 2. male), age (1. <45, 2. ≥45), T stage (1. T1, 2.
T2, 3. T3, 4. T4), N stage (1. N0, 2. N1, 3. N2, 4. N3),
Epstein–Barr virus deoxyribonucleic acid (EBV DNA)
(1. <4000, 2. ≥4000), and cumulative dose of cisplatin
(1. low-, 2. medium-, 3. high-dose group). The entire
patient cohort was divided into high- and low-risk pa-
tients by pre-treatment with EBV DNA using a cut-off
value of 4000 copies/ml, according to previous studies,
which led to a distinct risk stratification [22, 23]. The
following end-points (time to the first defining event)
were assessed: overall survival (OS), disease-free sur-
vival (DFS, distant metastasis-free survival (DMFS), and
locoregional relapse-free survival (LRFS). The OS was
defined as the time from diagnosis of NPC to death
from any cause or until the date of the last follow-up.
DFS was defined as the time from the diagnosis of NPC
to events that included death or disease progression at
local, regional, or distant sites or until the date of the
last follow-up. LRFS was defined as the time from the
diagnosis of NPC to the absence of a primary site or
neck lymph node relapse or until the date of the last
follow-up. DMFS was defined as the time from the date
of treatment to the date of the first observation of a
distant metastases or until the date of the last follow-
up. The primary endpoint was OS, and secondary end-
points were DFS, DMFS, and LRFS.
Multivariate analyses using the Cox proportional
hazards regression model were utilised to test for
independent significance. All P values were two-tailed;
P ≤ 0.05 was considered statistically significant. Our re-
port adheres to STROBE guidelines (http://www.strobe-
statement.org/) for reporting observational research
(Additional file 1).
Results
In total, 22/491 (4.5 %) patients developed locoregional
failure, 53/491 (10.8 %) patients developed distant
metastases, 39/491 (7.9 %) patients died, and 70/491
(14.3 %) patients developed both locoregional recur-
rences and distant metastases. For the entire cohort, the
5-year OS, DFS, DMFS, and LRFS rates were 90.1 %,
84.1 %, 88.2 %, and 94.8 %, respectively.
The clinical characteristics and prognosis impact of
cumulative doses of cisplatin
NPC patients received low- (≤100 mg/m2), medium-
(101–200 mg/m2), or high-doses (>200 mg/m2) of
cumulative cisplatin. The clinical characteristics and
treatment factors for the three groups (≤100 mg/m2,
101–200 mg/m2, >200 mg/m2) were well balanced. The
5-year OS rates of the low-, medium-, and high-dose
groups were 64.1 %, 91.1 %, and 89.4 %, respectively
(P = 0.002; Fig. 1). Multivariate analysis using the Cox
proportional hazards regression model demonstrated
that the cumulative dose of cisplatin was significantly
associated with OS (Table 2), and the N stage was an
independent prognostic factor for OS. Patients who
were in the medium- and high-dose groups had lower
odds of death than did the patients in the low-dose
group, with odds ratios of 0.135 (95 % confidence in-
tervals (CI) 0.045–0.405, P < 0.001) and 0.225 (95 % CI
0.069–0.734, P = 0.013), respectively. In addition, a sig-
nificant difference in OS was observed on the N stage and
EBV DNA. Patients with a N3 stage and EBV DNA ≥4000
copies/ml had an increased odd of death, with odds ratios
of 7.404 (95 % CI 1.494–36.684, P = 0.014) and 4.953
(95 % CI 2.200–11.153, P < 0.001), respectively.
The 5-year DMFS rates of the low-, medium-, and
high-dose groups were 69.2 %, 88.7 %, and 88.6 %,
respectively; this difference was statistically significant
(P = 0.027; Fig. 2). Multivariate analysis using the Cox
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proportional hazards model demonstrated that EBV DNA
was the only independent prognostic factor associated
with DMFS with an OR of 3.669 (95 % CI 2.058–6.540,
P < 0.001; Table 2). The cumulative dose of cisplatin
was not significantly associated with DFS or LRFS.
Analysis of the prognostic implications of the cumulative
dose of cisplatin among all patients stratified by EBV DNA
levels
There were 300 (61.1 %) and 191 (38.9 %) patients with
pre-treatment EBV DNA levels less than 4000 copies/ml
or EBV DNA ≥4000 copies/ml, respectively. In the low-
risk group, 8 (2.7 %) patients received less than 100 mg/
m2, 323 (77.3 %) patients received 101–200 mg/m2, and
60 (20.0 %) patients received more than 200 mg/m2. In
the subgroup analysis for low-risk group patients (EBV
DNA <4000 copies/ml), the cumulative dose of cisplatin
was significantly associated with a lower OS based on
univariate analysis (P < 0.001; Fig. 3). After multivariate
analysis using the Cox proportional hazards regression
model, the cumulative dose of cisplatin was significantly
associated with OS (P = 0.009). The medium-dose group
had reduced odds of death compared with the low-dose
group, with an odds ratio of 0.062 (95 % CI 0.001–0.347,
P = 0.002). The cumulative dose of cisplatin was signifi-
cantly associated with DMFS (P = 0.034; Fig. 4). However,
the cumulative dose of cisplatin was not significantly asso-
ciated with DMFS by multivariate analysis. Moreover, the
cumulative dose of cisplatin was not associated with OS or
DMFS among the high-risk (EBV DNA ≥4000 copies/ml)
patients by multivariate Cox regression analysis.
Discussion
Concurrent chemotherapy combined with IMRT has
been established as a standard of care for the treatment
of advanced NPC because of its excellent local control
and increased survival rates [24, 25]. Therefore, it is
necessary to re-evaluate the impact of the cumulative
dose of cisplatin on the clinical outcomes for NPC in
this new era of IMRT.
Fig. 1 Kaplan–Meier curves of overall survival according to the cumulative dose of cisplatin in 491 patients with locally advanced
nasopharyngeal carcinoma
Table 2 Multivariate analysis of prognostic factors in 491
nasopharyngeal carcinoma patients receiving IMRT
Endpoint Variable HR HR (95 % CI) P value
OS N Stage(0) Ref Ref 0.001
N Stage(1) 1.172 0.252- 5.453 0.839
N Stage(2) 1.767 0.393- 7.950 0.458
N Stage(3) 7.404 1.494- 36.684 0.014
Low-dose group Ref Ref 0.001
Median-dose group 0.135 0.045-0.405 <0.001
High-dose group 0.225 0.069-0.734 0.013
EBV DNA 4.953 2.200-11.153 <0.001
DMFS EBV DNA 3.669 2.058-6.540 <0.001
HR hazard ratio, CI confidence interval, Ref reference, OS overall survival, DMFS
distant metastasis free survival, EBV DNA Epstein–Barr virus deoxyribonucleic
acid. P value < 0.05 is statistically significant
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Fig. 2 Kaplan–Meier curves of distant metastasis-free survival according to the cumulative dose of cisplatin in 491 patients with locally advanced
nasopharyngeal carcinoma
Fig. 3 Kaplan–Meier curves of overall survival according to the cumulative dose of cisplatin in 300 low-risk patients with locally advanced
nasopharyngeal carcinoma
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Currently, to the best of our knowledge, no report has
addressed the impact of the dose of cisplatin on the clin-
ical outcomes on patients with NPC who were treated
with IMRT. Several studies have analysed the impact of
the dose of cisplatin on clinical outcomes of NPC using
conventional 2D and 3D conformal radiotherapy tech-
nology. A previous study reported that the number of
cycles of cisplatin delivered is an independent prognostic
factor for OS in patients with stage II–III NPC who are
undergoing concurrent chemoradiotherapy with weekly
cisplatin [12]; however, this was a retrospective study
that enrolled 241 patients and was mostly based on 2D
or 3D conventional radiotherapy [12]. The impact of the
cumulative dose of cisplatin on clinical outcomes of
NPC remains unknown in this era of IMRT.
Wei et al. retrospectively compared the long-term effi-
cacy of CCRT regimens (docetaxel vs. cisplatin), the cumu-
lative dose intensity of cisplatin (>200 vs. ≤200 mg/m2),
and the pre-treatment plasma levels of EBV DNA for naso-
pharyngeal carcinoma (NPC). This study showed that
cumulative cisplatin >200 mg/m2 improved the 5-year PFS
rates and significantly improved distant failure-free survival
compared with cumulative cisplatin of ≤200 mg/m2 in 214
NPC patients [13]. Lee et al. reported a combined analysis
of NPC-9901 and NPC-9902 Trials and found that the
dose of cisplatin during the concurrent phase had a signifi-
cant impact on the locoregional-failure free and OS rates;
the difference between 0–1 (0–100 mg/m2) and 2 cycles
(200 mg/m2) was significant [14]. The results of our study
were in accordance with previous studies. Our findings
suggest that the patients who received 0–100 mg/m2 of
cisplatin had lower OS and DMFS rates than did the pa-
tients who received >100 mg/m2 of cisplatin concurrent
chemotherapy among the 491 patients after multivariate
analysis.
There was no significant difference between the
patients in the medium- (101–200 mg/m2) and high-
(>200 mg/m2) dose groups. Future studies are needed to
evaluate whether low-risk patients who receive medium-
dose cisplatin chemotherapy gain the same long-term
survival benefit as those who receive high-dose cisplatin
chemotherapy. In Asian populations, the rate of compli-
ance with three cycles of cisplatin might be lower than
that observed for patients in Western nations. A total of
107 (68 %) patients completed all cycles of concurrent
chemotherapy in a clinical trial that compared concur-
rent chemoradiotherapy plus adjuvant chemotherapy
with radiotherapy alone in patients with locoregionally
advanced nasopharyngeal carcinoma in endemic regions
of China [26].
Tao et al. retrospectively analysed 154 patients to com-
pare the long-term survival and the toxicity of cisplatin
delivered weekly versus every three weeks concurrently
with IMRT in NPC. In the group receiving cisplatin
every three weeks, 88.9 % of the patients completed two
cycles of cisplatin, and only 6.2 % of the patients
Fig. 4 Kaplan–Meier curves of distant metastasis-free survival according to the cumulative dose of cisplatin in 300 low-risk patients with locally
advanced nasopharyngeal carcinoma
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received three cycles of cisplatin. In the weekly group,
90.4 % of the patients received at least five weeks of cis-
platin, and 5.5 % of the patients received seven weeks of
cisplatin [2]. Further clinical studies are required to in-
vestigate the balance between clinical outcomes and the
compliance with concurrent cisplatin chemotherapy and
thereby identify the appropriate dose of concurrent cis-
platin that is required to improve NPC patient
outcomes.
We observed that the cumulative dose of cisplatin
affected the overall survival and distant failure rates but
did not affect local failure rates in NPC patients treated
with IMRT. The main reason for this finding could be
the excellent dose coverage of the locoregional site that
is provided by IMRT. Indeed, the increasingly wide-
spread use of IMRT technology in NPC patients in
recent decades has improved treatment outcomes com-
pared with conventional radiotherapy, particularly for
local disease control [27–29]. The patterns of failure
after IMRT predominantly result from distant metasta-
ses rather than local control. Therefore, the optimal
cisplatin dose in CCRT regimes for NPC warrants fur-
ther exploration. It is possible that combined use of in-
duction chemotherapy or adjuvant chemotherapy with
cisplatin-based CCRT results in reducing the DMFS rate
on NPC patients treated with IMRT. Although the answer
for this question is still unclear, the results of ongoing
trials are expected to point out the benefits on DMFS
by using induction chemotherapy or adjuvant chemo-
therapy combined with CCRT compared to cisplatin-
based CCRT alone.
In our subgroup analysis of low-risk patients, the cu-
mulative dose of cisplatin had an impact on OS based
on the multivariate analysis. The results of the subgroup
analysis of low-risk patients were in accordance with the
results obtained for all patients. The low-risk group,
which received a dose of cisplatin ≤ 100 mg/m2, was
composed of only 8 patients, and therefore could be
biased. In the low-risk group, only 2 patients died. Both
of the patients died from distant metastases. There is an
unavoidable bias because of the small sample size in the
low-risk group receiving a dose of cisplatin ≤100 mg/m2.
However, there was no difference in the clinical out-
comes among the low-, medium-, and high-dose groups
for the high-risk patients. We speculate that the number
of high-risk patients was too small to detect any signifi-
cant differences among the groups. There were 191
high-risk patients in our study, which is not a very large
sample size. Thus, there is possible bias due to the small
sample size in the high-risk patient group. Increasing
the sample size in future studies will enable the further
evaluation of the cumulative dose of cisplatin among
high-risk patients with NPC with reduced bias. In
addition, the high-risk patients were usually with
high tumour burden, which probably progressing to
tumour distant metastasis. Therefore, for these high-
risk patients, concurrent chemoradiotherapy may not
be very effective.
The major drawback of this study is the limitations
due to the retrospective design. For example, the num-
ber of patients in the low-dose group was too small.
And the study included patients who received a three-
week regimen or a weekly regimen of cisplatin, which
leads to possible bias. We did not provide a suggestive
cisplatin delivery regimen or the optimal cumulative
cisplatin dose in this study. Further studies are needed
to confirm the optimal cumulative cisplatin dose and the
preferred delivery cisplatin regimen. In addition, it was a
single-centre study; therefore, these results need to be
validated in other data sets.
Conclusions
The cumulative dose of cisplatin is significantly associ-
ated with reduced OS and DMFS in patients who re-
ceived IMRT. The findings of this study are important
for further investigations into the appropriate cumulative
dose of cisplatin as a concurrent chemotherapy adminis-
tered in CCRT.
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